Curative Biotechnology, Inc.

OTCPK:CUBT Stock Report

Market Cap: US$10.1m

Curative Biotechnology Management

Management criteria checks 3/4

Curative Biotechnology's CEO is I. Garr, appointed in Feb 2021, has a tenure of 3.83 years. directly owns 13.89% of the company’s shares, worth $1.40M. The average tenure of the management team and the board of directors is 3.8 years and 2.9 years respectively.

Key information

I. Garr

Chief executive officer

US$438.0k

Total compensation

CEO salary percentagen/a
CEO tenure3.8yrs
CEO ownership13.9%
Management average tenure3.8yrs
Board average tenure2.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has I. Garr's remuneration changed compared to Curative Biotechnology's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$438kn/a

-US$6m

Dec 31 2022US$517kUS$158k

-US$5m

Sep 30 2022n/an/a

-US$6m

Jun 30 2022n/an/a

-US$6m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$3mUS$170k

-US$19m

Sep 30 2021n/an/a

-US$22m

Mar 31 2021n/an/a

-US$17m

Dec 31 2020US$980kn/a

-US$5m

Compensation vs Market: I.'s total compensation ($USD438.00K) is below average for companies of similar size in the US market ($USD650.86K).

Compensation vs Earnings: I.'s compensation has been consistent with company performance over the past year.

CEO

I. Garr (71 yo)

3.8yrs

Tenure

US$438,000

Compensation

Mr. I. Richard Garr, JD, Esq., serves as CEO, CFO, General Counsel at Connectyx Technologies Holdings Group, Inc. (formerly known as Curative Biotechnology, Inc.) since February 2021 and its Principal Acco...

Leadership Team

NamePositionTenureCompensationOwnership
Paul Michaels
President & Executive Chairman4.8yrsUS$783.11k6.95%
$ 702.7k
I. Garr
CEO, CFO3.8yrsUS$438.00k13.89%
$ 1.4m
Pam Bisikirski
Vice President of Communicationsno datano datano data
Ronald Bordens
Executive VP of Process Product Drug Development and Member of Scientific & Clinical Advisory Board3.8yrsno datano data

3.8yrs

Average Tenure

Experienced Management: CUBT's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul Michaels
President & Executive Chairman4.8yrsUS$783.11k6.95%
$ 702.7k
Ronald Bordens
Executive VP of Process Product Drug Development and Member of Scientific & Clinical Advisory Boardno datano datano data
Lawrence Zaslow
Independent Director2.5yrsno datano data
Cary Sucoff
Independent Director2.6yrsno datano data
Theressa G. Heah
Independent Directorless than a yearno datano data
Kapil Bharti
Member of Scientific & Clinical Advisory Board3.7yrsno datano data
Michael Grace
Chairman of the Scientific Advisory Board3.8yrsno datano data
Nicholas Boulis
Member of Scientific & Clinical Advisory Board3.3yrsno datano data
Thomas Poss
Independent Director1.7yrsno datano data

2.9yrs

Average Tenure

61yo

Average Age

Experienced Board: CUBT's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 05:26
End of Day Share Price 2024/12/20 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Curative Biotechnology, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution